Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Cai, Wei ^a   Duan, Xi Mei ^a,b   Liu, Ying ^a   Yu, Jiao ^a   Tang, Yun Liang ^a   Liu, Ze Lin ^a   Jiang, Shan ^a   Zhang, Chun Ping ^a   Liu, Jian Ying ^a   Xu, Ji Xiong ^a  

^a NANCHANG UNIVERSITY   (China)

^b People s Hospital of Shangrao City   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MESSENGER RNA; NITRIC OXIDE; TUMOR NECROSIS FACTOR; URIC ACID; VASCULAR CELL ADHESION MOLECULE 1; AGER PROTEIN, HUMAN; HMGB1 PROTEIN, HUMAN; NOS3 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYPERURICEMIA; INFLAMMATION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL ADHESION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; CELL ADHESION; CYTOKINES; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HMGB1 PROTEIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; URIC ACID;

EID: 85010402320     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/4391920     Document Type: Article

References (47)

1. R. J. Johnson, D.-H. Kang, D. Feig et al., "Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?" Hypertension, vol. 41, no. 6, pp. 1183-1190, 2003.
2. V. Vitart, I. Rudan, C. Hayward et al., "SLC2A9 is a newly iden-tified urate transporter infuencing serum urate concentration, urate excretion and gout," Nature Genetics, vol. 40, no. 4, pp. 437-442, 2008.
3. D. I. Feig, D.-H. Kang, T. Nakagawa, M. Mazzali, and R. J. Johnson, "Uric acid and hypertension," Current Hypertension Reports, vol. 8, no. 2, pp. 111-115, 2006.
4. S. Watanabe, D.-H. Kang, L. L. Feng et al., "Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity," Hypertension, vol. 40, no. 3, pp. 355-360, 2002.
5. M. H. Alderman, "Uric acid and cardiovascular risk," Current Opinion in Pharmacology, vol. 2, no. 2, pp. 126-130, 2002.
6. C. Zoccali, R. Maio, F. Mallamaci, G. Sesti, and F. Perticone, "Uric acid and endothelial dysfunction in essential hypertension," Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1466-1471, 2006.
7. E. Agabiti-Rosei and G. Grassi, "Beyond gout: uric acid and cardiovascular diseases," Current Medical Research and Opinion, vol. 29, no. 3, pp. 33-39, 2013.
8. S. D. Anker, W. Doehner, M. Rauchhaus et al., "Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging," Circulation, vol. 107, no. 15, pp. 1991-1997, 2003.
9. U. M. Khosla, S. Zharikov, J. L. Finch et al., "Hyperuricemia induces endothelial dysfunction," Kidney International, vol. 67, no. 5, pp. 1739-1742, 2005.
10. W. Doehner, N. Schoene, M. Rauchhaus et al., "Efects of xan-thine oxidase inhibition with allopurinol on endothelial function and peripheral blood fow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies," Circulation, vol. 105, no. 22, pp. 2619-2624, 2002.
11. D. I. Feig and R. J. Johnson, "Hyperuricemia in childhood primary hypertension," Hypertension, vol. 42, no. 3, pp. 247-252, 2003.
12. D. I. Feig and R. J. Johnson, "Te role of uric acid in pediatric hypertension," Journal of Renal Nutrition, vol. 17, no. 1, pp. 79-83, 2007.
13. D. I. Feig, D.-H. Kang, and R. J. Johnson, "Uric acid and cardiovascular risk," The New England Journal of Medicine, vol. 359, no. 17, pp. 1811-1821, 2008.
14. 2+ exchanger-mediated mitochondrial calcium overload," Cell Calcium, vol. 51, no. 5, pp. 402-410, 2012.
15. D. I. Jalal, D. M. Maahs, P. Hovind, and T. Nakagawa, "Uric acid as a mediator of diabetic nephropathy," Seminars in Nephrology, vol. 31, no. 5, pp. 459-465, 2011.
16. E. Manzato, "Uric acid: an old actor for a new role," Internal and Emergency Medicine, vol. 2, no. 1, pp. 1-2, 2007.
17. K. L. Rock, H. Kataoka, and J.-J. Lai, "Uric acid as a danger signal in gout and its comorbidities," Nature Reviews Rheumatology, vol. 9, no. 1, pp. 13-23, 2013.
18. T. Lyngdoh, P. Marques-Vidal, F. Paccaud et al., "Elevated serum uric acid is associated with high circulating infammatory cytokines in the population-based colaus study," PLoS ONE, vol. 6, no. 5, article e19901, 2011.
19. A. Bierhaus, P. M. Humpert, M. Morcos et al., "Understanding RAGE, the receptor for advanced glycation end products," Journal of Molecular Medicine, vol. 83, no. 11, pp. 876-886, 2005.
20. A. M. Schmidt, S. D. Yan, J.-L. Wautier, and D. Stern, "Activation of receptor for advanced glycation end products-a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis," Circulation Research, vol. 84, no. 5, pp. 489-497, 1999.
21. R. Ross, "Atherosclerosis-an infammatory disease-reply," The New England Journal of Medicine, vol. 340, no. 2, pp. 115-126, 1999.
22. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, "Advanced glycation end products: sparking the development of diabetic vascular injury," Circulation, vol. 114, no. 6, pp. 597-605, 2006.
23. A. Soro-Paavonen, A. M. D. Watson, J. Li et al., "Receptor for advanced glycation end products (RAGE) defciency attenuates the development of atherosclerosis in diabetes," Diabetes, vol. 57, no. 9, pp. 2461-2469, 2008.
24. S. F. Yan, R. Ramasamy, and A. M. Schmidt, "Te RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature," Circulation Research, vol. 106, no. 5, pp. 842-853, 2010.
25. G. Basta, G. Lazzerini, M. Massaro et al., "Advanced glyca-tion end products activate endothelium through signal-trans-duction receptor RAGE: a mechanism for amplification of infammatory responses," Circulation, vol. 105, no. 7, pp. 816-822, 2002.
26. R. Ramasamy, S. F. Yan, and A. M. Schmidt, "Te rage axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond," Trends in Cardiovascular Medicine, vol. 15, no. 7, pp. 237-243, 2005.
27. U. G. Andersson and K. J. Tracey, "HMGB1, a pro-infammatory cytokine of clinical interest: introduction," Journal of Internal Medicine, vol. 255, no. 3, pp. 318-319, 2004.
28. H. C. Wang, O. Bloom, M. H. Zhang et al., "HMG-1 as a late mediator of endotoxin lethality in mice," Science, vol. 285, no. 5425, pp. 248-251, 1999.
29. W. Lee, S.-K. Ku, J. W. Bae, and J.-S. Bae, "Inhibitory effects of lycopene on HMGB1-mediated pro-infammatory responses in both cellular and animal models," Food and Chemical Toxicology, vol. 50, no. 6, pp. 1826-1833, 2012.
30. M. M. Rabadi, M.-C. Kuo, T. Ghaly et al., "Interaction between uric acid and HMGB1 translocation and release from endothe-lial cells," American Journal of Physiology-Renal Physiology, vol. 302, no. 6, pp. F730-F741, 2012.
31. H. K. Choi, D. B. Mount, and A. M. Reginato, "Pathogenesis of gout," Annals of Internal Medicine, vol. 143, no. 7, pp. 499-516, 2005.
32. M. A. Becker and M. Jolly, "Hyperuricemia and associated diseases," Rheumatic Disease Clinics of North America, vol. 32, no. 2, pp. 275-293, 2006.
33. Y. S. Kim, J. P. Guevara, K. M. Kim, H. K. Choi, D. F. Heitjan, and D. A. Albert, "Hyperuricemia and coronary heart disease: a systematic review and meta-analysis," Arthritis Care & Research, vol. 62, no. 2, pp. 170-180, 2010.
34. M. Li, W. Hou, X. Zhang, L. Hu, and Z. Tang, "Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies," Atherosclerosis, vol. 232, no. 2, pp. 265-270, 2014.
35. P. O. Bonetti, L. O. Lerman, and A. Lerman, "Endothelial dysfunction-a marker of atherosclerotic risk," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 23, no. 2, pp. 168-175, 2003.
36. J. Davignon and P. Ganz, "Role of endothelial dysfunction in atherosclerosis," Circulation, vol. 109, no. 23, supplement 1, pp. III27-III32, 2004.
37. L. G. Sánchez-Lozada, M. A. Lanaspa, M. Cristóbal-García et al., "Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations," Nephron-Experimental Nephrology, vol. 121, no. 3-4, pp. e71-e78, 2013.
38. D. B. Corry and M. L. Tuck, "Uric acid and the vasculature," Current Hypertension Reports, vol. 8, no. 2, pp. 116-119, 2006.
39. P. Puddu, G. M. Puddu, E. Cravero, L. Vizioli, and A. Muscari, "Te relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: molecular mechanisms and clinical implications," Journal of Cardiology, vol. 59, no. 3, pp. 235-242, 2012.
40. E. Biros, C. S. Moran, P. E. Norman et al., "Association between the advanced glycosylation end product-specifc receptor gene and cardiovascular death in older men," PLoS ONE, vol. 10, no. 7, Article ID e0134475, 2015.
41. M. B. Manigrasso, J. Juranek, R. Ramasamy, and A. M. Schmidt, "Unlocking the biology of RAGE in diabetic microvascular complications," Trends in Endocrinology & Metabolism, vol. 25, no. 1, pp. 15-22, 2014.
42. L. Lin, S. Park, and E. G. Lakatta, "RAGE signaling in infam-mation and arterial aging," Frontiers in Bioscience, vol. 14, no. 4, pp. 1403-1413, 2009.
43. P. Huebener, C. Hernandez, and R. F. Schwabe, "HMGB1 and injury amplification," Oncotarget, vol. 6, no. 27, pp. 23048-23049, 2015.
44. D. Tang, R. Kang, H. J. Zeh, and M. T. Lotze, "High-mobility group box 1, oxidative stress, and disease," Antioxidants and Redox Signaling, vol. 14, no. 7, pp. 1315-1335, 2011.
45. D. J. Weber, A. S. Gracon, M. S. Ripsch et al., "Te HMGB1-RAGE axis mediates traumatic brain injury-induced pulmonary dysfunction in lung transplantation," Science Transla-tional Medicine, vol. 6, no. 252, pp. 5140-5144, 2014.
46. E. Harja, D.-X. Bu, B. I. Hudson et al., "Vascular and infamma-tory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice," The Journal of Clinical Investigation, vol. 118, no. 1, pp. 183-194, 2008.
47. Z.-G. Luan, H. Zhang, P.-T. Yang, X.-C. Ma, C. Zhang, and R.-X. Guo, "HMGB1 activates nuclear factor-αBsignalingbyRAGE and increases the production of TNF-α in human umbilical vein endothelial cells," Immunobiology, vol. 215, no. 12, pp. 956-962, 2010.